A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Inclusion Criteria:
Exclusion Criteria:
Kralove, Czechia
Kerala, India
Grosseto GR, Italy
Kelantan, Malaysia
RM Groningen, Netherlands
Gauteng, South Africa
Kaohsiung Hsien, Taiwan
Kweishan, Taiwan
Ubonratchathani Province, Thailand